The first interoperable insulin pump — meaning it can work with a variety of other components to form a comprehensive diabetes treatment system — was authorized for marketing by the FDA this week.
In other FDA news, the agency also cleared Sciton’s laser device diVa to carry the new indication to include the treatment for genitourinary syndrome of menopause.
A 73 year old Florida man was arrested after posing as a doctor claiming to have a cure for diabetes. (New York Post)
Top-line results from the CAROLINA cardiovascular outcome trial found linagliptin (Tradjenta) was non-inferior to glimepiride for time to MACE events in people with type 2 diabetes, Boehringer Ingelheim and Eli Lilly announced.
Drinking a lot of diet sodas was tied to a higher risk for stroke, heart disease, and all-cause mortality in a large study. “We don’t know specifically what types of artificially sweetened beverages they were consuming, so we don’t know which artificial sweeteners may be harmful and which may be harmless, said lead author Yasmin Mossavar-Rahmani, PhD, of Albert Einstein College of Medicine in New York, in a statement. (Stroke)
Sojournix announced positive top-line phase I findings with a neurokinin-3 antagonist for menopausal vasomotor symptoms, SJX-653.
Far fewer older men with osteoporosis at high risk for fracture underwent DXA scans, received vitamin D and calcium supplements, or bisphosphonate prescriptions, compared with older women. (Journal of Investigative Medicine)
A $12.5-million NIH grant went to Icahn School of Medicine at Mount Sinai researchers looking at how follicle-stimulating hormone plays into osteoporosis and obesity.